330 related articles for article (PubMed ID: 26982238)
1. Schedule-dependent interaction between temsirolimus and cetuximab in head and neck cancer: a preclinical study.
Lattanzio L; Milano G; Monteverde M; Tonissi F; Vivenza D; Merlano M; Lo Nigro C
Anticancer Drugs; 2016 Jul; 27(6):533-9. PubMed ID: 26982238
[TBL] [Abstract][Full Text] [Related]
2. Combination of mTOR and EGFR targeting in an orthotopic xenograft model of head and neck cancer.
Bozec A; Ebran N; Radosevic-Robin N; Sudaka A; Monteverde M; Toussan N; Etienne-Grimaldi MC; Nigro CL; Merlano M; Penault-Llorca F; Milano G
Laryngoscope; 2016 Apr; 126(4):E156-63. PubMed ID: 26597440
[TBL] [Abstract][Full Text] [Related]
3. CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab.
Niehr F; Weichert W; Stenzinger A; Budach V; Tinhofer I
J Transl Med; 2015 Apr; 13():106. PubMed ID: 25890004
[TBL] [Abstract][Full Text] [Related]
4. The mTOR-targeting drug temsirolimus enhances the growth-inhibiting effects of the cetuximab-bevacizumab-irradiation combination on head and neck cancer xenografts.
Bozec A; Etienne-Grimaldi MC; Fischel JL; Sudaka A; Toussan N; Formento P; Milano G
Oral Oncol; 2011 May; 47(5):340-4. PubMed ID: 21421338
[TBL] [Abstract][Full Text] [Related]
5. Treatment effect of buparlisib, cetuximab and irradiation in wild-type or PI3KCA-mutated head and neck cancer cell lines.
Lattanzio L; Tonissi F; Monteverde M; Vivenza D; Russi E; Milano G; Merlano M; Lo Nigro C
Invest New Drugs; 2015 Apr; 33(2):310-20. PubMed ID: 25603975
[TBL] [Abstract][Full Text] [Related]
6. A positive feedback loop involving EGFR/Akt/mTORC1 and IKK/NF-kB regulates head and neck squamous cell carcinoma proliferation.
Li Z; Yang Z; Passaniti A; Lapidus RG; Liu X; Cullen KJ; Dan HC
Oncotarget; 2016 May; 7(22):31892-906. PubMed ID: 26895469
[TBL] [Abstract][Full Text] [Related]
7. mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations.
Wang Z; Martin D; Molinolo AA; Patel V; Iglesias-Bartolome R; Degese MS; Vitale-Cross L; Chen Q; Gutkind JS
J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25099740
[TBL] [Abstract][Full Text] [Related]
8. A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO study.
Seiwert TY; Kochanny S; Wood K; Worden FP; Adkins D; Wade JL; Sleckman BG; Anderson D; Brisson RJ; Karrison T; Stadler WM; Vokes EE
Cancer; 2020 Jul; 126(14):3237-3243. PubMed ID: 32365226
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms underlying resistance to cetuximab in the HNSCC cell line: role of AKT inhibition in bypassing this resistance.
Rebucci M; Peixoto P; Dewitte A; Wattez N; De Nuncques MA; Rezvoy N; Vautravers-Dewas C; Buisine MP; Guerin E; Peyrat JP; Lartigau E; Lansiaux A
Int J Oncol; 2011 Jan; 38(1):189-200. PubMed ID: 21109940
[TBL] [Abstract][Full Text] [Related]
10. ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis.
Lu H; Li X; Lu Y; Qiu S; Fan Z
Cancer Lett; 2016 Oct; 381(1):23-30. PubMed ID: 27450723
[TBL] [Abstract][Full Text] [Related]
11. Dual Targeting of Epidermal Growth Factor Receptor and HER3 by MEHD7945A as Monotherapy or in Combination with Cisplatin Partially Overcomes Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma Cell Lines.
De Pauw I; Wouters A; Van den Bossche J; Deschoolmeester V; Baysal H; Pauwels P; Peeters M; Vermorken JB; Lardon F
Cancer Biother Radiopharm; 2017 Sep; 32(7):229-238. PubMed ID: 28910149
[TBL] [Abstract][Full Text] [Related]
12. Cetuximab sensitivity of head and neck squamous cell carcinoma xenografts is associated with treatment-induced reduction in EGFR, pEGFR, and pSrc.
Jedlinski A; Garvin S; Johansson AC; Edqvist PH; Ponten F; Roberg K
J Oral Pathol Med; 2017 Oct; 46(9):717-724. PubMed ID: 28036101
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma.
Bauman JE; Arias-Pulido H; Lee SJ; Fekrazad MH; Ozawa H; Fertig E; Howard J; Bishop J; Wang H; Olson GT; Spafford MJ; Jones DV; Chung CH
Oral Oncol; 2013 May; 49(5):461-7. PubMed ID: 23384718
[TBL] [Abstract][Full Text] [Related]
14. Combination of phosphotidylinositol-3-kinase targeting with cetuximab and irradiation: A preclinical study on an orthotopic xenograft model of head and neck cancer.
Bozec A; Ebran N; Radosevic-Robin N; Chamorey E; Yahia HB; Marcie S; Gautier M; Penault-Llorca F; Milano G
Head Neck; 2017 Jan; 39(1):151-159. PubMed ID: 27507562
[TBL] [Abstract][Full Text] [Related]
15. Novel HSP90 inhibitor NVP-AUY922 enhances the anti-tumor effect of temsirolimus against oral squamous cell carcinoma.
Okui T; Shimo T; Fukazawa T; Mohammad Monsur Hassan N; Honami T; Ibaragi S; Takaoka M; Naomoto Y; Sasaki A
Curr Cancer Drug Targets; 2013 Mar; 13(3):289-99. PubMed ID: 23016912
[TBL] [Abstract][Full Text] [Related]
16. Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck.
Saba NF; Hurwitz SJ; Magliocca K; Kim S; Owonikoko TK; Harvey D; Ramalingam SS; Chen Z; Rogerio J; Mendel J; Kono SA; Lewis C; Chen AY; Higgins K; El-Deiry M; Wadsworth T; Beitler JJ; Shin DM; Sun SY; Khuri FR
Cancer; 2014 Dec; 120(24):3940-51. PubMed ID: 25103371
[TBL] [Abstract][Full Text] [Related]
17. Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC.
Swick AD; Prabakaran PJ; Miller MC; Javaid AM; Fisher MM; Sampene E; Ong IM; Hu R; Iida M; Nickel KP; Bruce JY; Wheeler DL; Kimple RJ
Mol Cancer Ther; 2017 Jul; 16(7):1257-1268. PubMed ID: 28446642
[TBL] [Abstract][Full Text] [Related]
18. Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab.
Ather F; Hamidi H; Fejzo MS; Letrent S; Finn RS; Kabbinavar F; Head C; Wong SG
PLoS One; 2013; 8(2):e56112. PubMed ID: 23405260
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor is a potential biomarker for poor cetuximab response in tongue cancer cells.
Ansell A; Jedlinski A; Johansson AC; Roberg K
J Oral Pathol Med; 2016 Jan; 45(1):9-16. PubMed ID: 25677871
[TBL] [Abstract][Full Text] [Related]
20. Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer.
Keysar SB; Le PN; Anderson RT; Morton JJ; Bowles DW; Paylor JJ; Vogler BW; Thorburn J; Fernandez P; Glogowska MJ; Takimoto SM; Sehrt DB; Gan GN; Eagles-Soukup JR; Serracino H; Hirsch FR; Lucia MS; Thorburn A; Song JI; Wang XJ; Jimeno A
Cancer Res; 2013 Jun; 73(11):3381-92. PubMed ID: 23576557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
